X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215063
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215081
https://www.reuters.com/markets/deals/bausch-lomb-buy-dry-eye-drug-novartis-175-billion-wsj-2023-06-30/
https://www.fiercepharma.com/pharma/after-34b-deal-and-eu-withdrawal-novartis-wants-xiidra-gone-sale-some-eye-meds-bloomberg
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215058
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215126
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-15-2022-1655268880.pdf
https://uk.reuters.com/article/us-takeda-pharma-xiidra/japans-takeda-expects-200-million-operating-loss-related-to-novartis-xiidra-withdrawal-idUKKBN2400AP
https://endpts.com/novartis-yanks-application-from-the-ema-after-regulators-say-researchers-never-proved-efficacy-of-their-3-4b-dry-eye-drug/
https://www.fiercepharma.com/marketing/novartis-seeing-no-hope-for-approval-pulls-takeda-bought-dry-eye-med-xiidra-europe
https://www.fiercepharma.com/marketing/chasing-gw-s-epidiolex-zogenix-finally-wins-fda-nod-for-rare-childhood-epilepsy-drug
https://www.fiercepharma.com/manufacturing/takeda-recalls-eye-drug-natpara-but-warns-patients-not-to-abruptly-stop-treatment
https://endpts.com/fda-rejects-kalas-dry-eye-drug-troubled-insys-finds-a-buyer-of-some-assets-in-hikma/
https://www.fiercepharma.com/pharma/takeda-seeks-buyer-for-european-otc-off-patent-drugs-worth-eu1-5b-report
https://www.fiercepharma.com/pharma/novartis-offloads-lagging-endocrine-drugs-pipeline-followup-to-recordati-for-390m?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/shire-deal-haunts-takeda-ceo-as-investors-want-execs-to-return-pay-if-performance-lags?utm_source=internal&utm_medium=rss
https://endpts.com/aldeyras-eye-drug-stumbles-in-pivotal-test-in-patients-with-rare-inflammatory-disease/
https://www.biospectrumasia.com/news/50/13423/novartis-to-acquire-xiidra-in-a-5-3b-deal.html
https://www.cnbc.com/2019/05/08/reuters-america-update-2-takeda-sells-dry-eye-drug-to-novartis-to-help-cut-debt.html
https://www.fiercebiotech.com/sponsored/mitotech-a-dry-eye-treatment-aimed-at-mitochondria
https://www.fiercepharma.com/pharma/3b-emerging-market-assets-could-be-next-takeda-s-chopping-board-report
https://www.biospace.com/article/takeda-may-sell-early-stage-drug-to-appease-european-regulators-before-shire-acquisition/?s=79
https://www.biopharmadive.com/news/aldeyra-has-positive-dry-eye-data-for-now/533299/
https://www.bloomberg.com/news/articles/2018-09-13/takeda-is-said-to-weigh-sale-of-shire-eye-care-drug-to-cut-debt
https://www.cnbc.com/2018/09/13/reuters-america-takeda-weighs-sale-of-shires-eye-care-business-to-cut-debt-bloomberg.html
https://endpts.com/hoping-to-shake-allergan-shires-dry-eye-dominance-oyster-point-posts-positive-phase-iib-data-for-rival-drug/
https://www.biospectrumasia.com/news/25/10495/wize-pharma-appoints-joseph-tauber-on-scientific-advisory-board.html
http://www.telegraph.co.uk/business/2017/08/15/shire-seeks-european-approval-dry-eye-disease-drops/
http://www.pmlive.com/pharma_news/shire_licences_parion_dry_eye_drug_in_$535m_deal_1192208
http://www.fiercepharma.com/drug-delivery/allergan-s-multi-dose-restasis-nabs-fda-approval-heads-shire-s-xiidra
http://www.pharmatimes.com/news/novartis_takes_home_rights_to_lubris_eye_drug_1191001
http://www.fiercepharma.com/marketing/allergan-encourages-dry-eye-sufferers-to-find-eyepowerment-latest-awareness-effort
http://www.fiercepharma.com/marketing/allergan-takes-preventable-blindness-nationwide-vision-screening-push
http://www.fiercepharma.com/pharma/mylan-scores-patent-review-allergan-s-restasis-but-analysts-aren-t-worried-about-eye
http://www.fiercepharma.com/pharma-asia/sun-pharma-buys-ocular-adding-late-stage-dry-eye-candidate-to-take-allergan-blockbuster
Market Place
Share 
